Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-2910 for CIPN Prevention in Breast Cancer
NCT06538272Phase 2Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Aug 2023
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chemotherapy-induced peripheral neuropathy (CIPN) comparing ONO-2910 Arm with Placebo Arm (2 arms). Primary endpoint: Proportion of participants with peripheral sensory neuropathy (NP) of Grade 2 or higher at 12 weeks. Started Aug 2023; status: completed.
02
Drugs
ONO-2910
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on NCT06538272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06538272.